ANTIGENICS INC /DE/ Form 8-K June 11, 2009

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

June 5, 2009

Date of Report (Date of earliest event reported)

ANTIGENICS INC.

(Exact name of registrant as specified in its charter)

DELAWARE (State or other jurisdiction

000-29089 (Commission File Number) 06-1562417 (IRS Employer

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

of incorporation)	Identification No.)
3 Forbes Road	
Lexington, MA (Address of principal executive offices) 781-67	02421 (Zip Code) 4-4400
	umber, including area code)
ck the appropriate box below if the Form 8-K filing is intended to sinfollowing provisions (see General Instruction A.2. below):	multaneously satisfy the filing obligation of the registrant under any of
 Written communications pursuant to Rule 425 under the Securities	Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Ad	et (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) un	der the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) un	der the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

Item 1.01 Entry into a Material Definitive Agreement.

On June 5, 2009, Antigenics Inc. entered into Amendment Number Two to the License Agreement between the University of Connecticut Health Center (UConn) and Antigenics Inc. effective May 25, 2001, as amended, modifying the annual maintenance fees payable to UConn.

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTIGENICS INC.

Date: June 11, 2009

By: /s/ Shalini Sharp

Shalini Sharp

Chief Financial Officer